Pfizer on Friday said the Covid pandemic will continue through the 2022 midterms and could extend to 2024.
Pfizer Inc (PFE.N) on Friday forecast that the COVID-19 pandemic would not be behind us until 2024 and said a lower-dose version of its vaccine for 2- to 4-year-olds generated a weaker immune response than expected, potentially delaying authorization.
Pfizer Chief Scientific Officer Mikael Dolsten said in a presentation to investors that the company expects some regions to continue to see pandemic levels of COVID-19 cases over the next year or two. Other countries will transition to “endemic” with low, manageable caseloads during that same time period.
By 2024, the disease should be endemic around the globe, the company projected.
Last week Pfizer CEO Albert Bourla said people will need a fourth jab sooner than expected.
Bourla told CNBC that his company is conducting studies on the Omicron variant and so far the results show a third jab is effective at fighting the new variant.
However, Bourla is already gearing up for a fourth jab – another booster for people and a booster for his company’s stock price.